CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.

doi:10.1200/JCO-25-01840

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2026

Jackson-Spence Francesca, Larkin James, Patel Poulam, Valderrama Begoña P, Rodriguez-Vida Alejo, Glen Hilary, Thistlethwaite Fiona C, Ralph Christy, Srinivasan Gopalakrishnan, Mendez-Vidal Maria Jose, Childress Merrida, Li Wenshu, Boyle Patrick, Gascó Amaya, Markovets Aleksandra, Hartmaier Ryan, Ackerman Charlotte, Szabados Bernadett E, Priyadarshini Garima, Jamal Fahmida, Powles Thomas, Suárez Cristina

Abstract excerpt

PURPOSE: The CALYPSO study demonstrated activity of savolitinib and durvalumab in MET-driven papillary renal cancer (PRC). We report final efficacy outcomes and exploratory circulating tumor DNA (ctDNA) biomarker analysis. METHODS: This single-arm phase II study evaluated savolitinib and durvalumab in treatment-naïve or pretreated PRC. End points included overall response rate (ORR), progression-free survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Renal Cell

Share to Circulating Tumor DNA

Share to Kidney Neoplasms

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins c-met

Share to Triazines

Source

Open in PubMed

Identifiers

PMID: 41861260
DOI: 10.1200/JCO-25-01840

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.PMID 41861260Read ↗

Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.Semantic proximity Read ↗

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.Semantic proximity Read ↗

Concurrent tissue and circulating tumor DNA analysis in renal cell carcinoma: insights from a multimodal database.Semantic proximity Read ↗

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.Semantic proximity Read ↗

Papillary renal cell carcinoma: A review of the current therapeutic landscape.Semantic proximity Read ↗

Papillary renal cell carcinoma: current progress and future directions.Semantic proximity Read ↗

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.Semantic proximity Read ↗

A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Semantic proximity Read ↗

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.Semantic proximity Read ↗

Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.